研究领域

Andrew Lee is an Associate Professor at Peking University Shenzhen Graduate School, School of Chemical Biology and Biotechnology and holds a joint appointment in the Institute of Cancer Research, Shenzhen Bay Laboratory. Andrew received his B.S. from Yale University, and his MD and PhD degrees from Stanford University. He completed his medical residency at Stanford Hospital in the Department of Clinical Pathology, where he focused on clinical manufacturing of cell / gene therapies for first in human clinical trials. He has published over 60 manuscripts on advancing cell and gene therapies into new clinical applications. 

Andrew's research on cell / gene therapy has published in Nature Medicine, Nature Biotechnology, Nature Biomedical Engineering, Cell, JAMA, and Circulation among other journals. According to Google Scholar, he has been cited over 9,000 times with an H-index of 40. Andrew's research has received support from the American Heart Association, Howard Hughes Medical Institute, and several of the global top 10 pharmaceutical companies.

代表论文

1. Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, Chien MH, Zhang ZX, Hsu WH, Wang X, Zhang J, Li H, Sun L, Fallen S, Lee I, Chen XY, Chu YS, Zhang X, Cheng TS, Jiang W, Kim BYS, Reategui E, Lee R, Yuan Y, Liu HC, Wang K, Hsiao M, Huang CYF^#, Shan YS^#, Lee AS^#, Lee LJ^#. Dual targeted extracellular vesicles regulate oncogenic genes in advances pancreatic cancer. Nature Communications 2023;14(1):6692. ^# = co-corresponding author. Impact Factor = 17.69

2. You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F^#, Kim BYS^#, Lee AS^#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy. Nature Biomedical Engineering 2023;1-13. ^# = corresponding author. Impact Factor = 29.23

3. Zhao L*, Lee AS*, Sasagawa K*, Sokol J, Wang Y, Ransom RC, Zhao X, Ma C, Steininger HM, Koepke LS, Borrelli MR, Brewer RE, Lee LLY, Huang X, Ambrosi TH, Sinha R, Hoover MY, Seita J, Weissman IL, Wu JC, Wan DC, Xiao J, Longaker MT, Nguyen PK, Chan CKF. Combination of distinct vascular stem / progenitor cells for neovascularization and ischemic rescue. Arteriosclerosis, Thrombosis, and Vascular Biology 2023: https://doi.org/10.1161/ATVBAHA.122.317943. *=equal contribution. Impact Factor = 10.51

4. Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H, Lee AS^#, Wang Y^#, Lan F^#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling. Cell Death and Disease 2019;8(13):1-15. ^# = co-corresponding author. Impact Factor = 12.07

5. Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease. Nature Biomedical Engineering 2018;2(2):104-113. *=equal contribution

Impact Factor = 29.23